Innate Immunotherapeutics Limited
Climate Impact & Sustainability Data (2014, 2015)
Reporting Period: 2014
Environmental Metrics
Governance Achievements
- Migrated place of incorporation from New Zealand to Australia.
- Listed shares on the Australian Securities Exchange (ASX).
Climate Goals & Targets
Short-term Goals:
- Complete Phase 2B trial by end of 2015
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations
Reporting Period: 2015
Environmental Metrics
Climate Goals & Targets
Medium-term Goals:
- Preclinical research into a potential oral formulation of MIS416.
Short-term Goals:
- Timely delivery of a successful Phase 2B trial result in patients with SPMS.
Environmental Challenges
- Patient recruitment for the Phase 2B trial took longer than originally forecast due to tight patient eligibility requirements and limited trial site availability.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations (3rd Edition)
Third-party Assurance: Grant Thornton Audit Pty Ltd